Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Late cornified envelope protein 2B (LCE2B) is a structural protein that acts as a precursor for the cornified envelope, which forms the outermost barrier of the skin (stratum corneum)[1][4]. It belongs to the late cornified envelope (LCE) protein family, a component of the epidermal differentiation complex (EDC) on chromosome 1q21[3][7]. LCE2B is highly expressed in the skin, especially during terminal keratinocyte differentiation, and is upregulated in certain skin conditions such as psoriasis[1][11]. The protein helps establish and reinforce the skin’s barrier function, crucial for protecting underlying tissues and maintaining hydration. While its primary function is structural, genetic variation or altered expression of LCE2B and related proteins has been implicated in several skin diseases, notably psoriasis[1][3]. No drugs are currently known to specifically target LCE2B, and it is not considered a classical therapeutic target such as a receptor, enzyme, ion channel, or transporter[1][3][11].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Late cornified envelope protein 2B (LCE2B).